Feasibility Study on LITT for Medical Refractory Epilepsy

Monteris Medical

Status: Terminated

Conditions: Epilepsy

Treatments: Device: NeuroBlate System

Study type: Interventional

Funder types: Industry

Identifiers

NCT02820740

FLARE

Details and patient eligibility

About

Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System for the treatment of drug-refractory medial temporal lobe epilepsy in subjects who are candidates for LITT surgery.

Full description

Monteris is sponsoring this multicenter, open-label, prospective feasibility study to characterize the performance of laser interstitial thermal therapy (LITT) using the Monteris NeuroBlate System for the treatment of drug-refractory medial temporal lobe epilepsy in subjects who are candidates for LITT surgery.

The NeuroBlate System uses precise, high-intensity laser light to initiate necrosis of abnormal brain tissue through thermal ablation while limiting injury to healthy tissue. Unlike traditional brain surgery, LITT does not require a large opening in the skull.

Subjects who meet the study eligibility criteria and sign the informed consent form will undergo the LITT procedure. Subjects, or their caregivers, are required to keep a seizure diary throughout the study, beginning after surgery. The study will monitor and record subjects' seizure frequency, antiepileptic medications, and physical and emotional health.

Subjects treated with NeuroBlate will have 2 years of follow-up. Throughout study participation, the study investigator will continuously monitor and document both effectiveness and safety data at study appointments.

Enrollment: 4 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Relevant Inclusion Criteria are listed below

• Diagnosis of unilateral medial temporal lobe epilepsy (MTLE) confirmed clinically and with either (1) ictal scalp recording and MRI evidence of mesial temporal sclerosis or (2) intracranial ictal onset consistent with hippocampal origin
• Averages 1 or more complex partial seizures or secondary generalized seizures compatible with MTLE per month
• On stable antiepileptic medications
• Meets the criteria for a medial temporal lobe resection and is a candidate for LITT
• 18 years or older at the time of consent

Relevant Exclusion Criteria are listed below

• Previous diagnosis of psychogenic/non-epileptic seizures
• Previous diagnosis of primary generalized seizures
• IQ less than 70
• Subject has a MRI-incompatible implanted electronic device or any metallic prosthesis or implant for which brain MRI is contraindicated

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

4 participants in 1 patient group

NeuroBlate LITT Treatment

Other group

Description:

This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System.

Treatment:

Device: NeuroBlate System